Cargando…

T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report

RATIONALE: T-cell lymphoma is a neoplasm that expresses markers of T-cell or natural killer cell (NK)-origin but not those of B-cell origin. Although B-cell lymphoma with abundant expression of T-cell markers exist, the opposite is very rare. Therefore, little is known about this subtype of lymphoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Yajuan, Bai, Chunmei, Sun, Jian, Gao, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895354/ https://www.ncbi.nlm.nih.gov/pubmed/29561444 http://dx.doi.org/10.1097/MD.0000000000010199

Ejemplares similares

Management of adverse effects associated with pegylated Escherichia coli asparaginase on coagulation in the treatment of patients with NK/T-cell lymphoma
por: Yang, Jing, et al.
Publicado: (2022)

A case report on the effect of rituximab on pyothorax-associated lymphoma
por: Wang, Fei, et al.
Publicado: (2019)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Li, Doudou, et al.
Publicado: (2015)

Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
por: Paule, Bernard, et al.
Publicado: (2010)

Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study
por: Mi, Mi, et al.
Publicado: (2020)

GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
por: Wang, Jing-jing, et al.
Publicado: (2016)

Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report
por: Cerchione, Claudio, et al.
Publicado: (2020)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Primary Thyroid Extranasal NK/T-Cell Lymphoma Associated With Good Outcome: A Case Report and Literature Review: A Care-Compliant Article
por: Li, Jun-he, et al.
Publicado: (2016)

Primary nasal diffuse large B-cell lymphoma with synchronous pulmonary involvement: A case report
por: Hao, Shuhong, et al.
Publicado: (2019)

A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin
por: Cherniawsky, Hannah, et al.
Publicado: (2017)

Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
por: Nakano, Shintaro, et al.
Publicado: (2020)

Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?: Case Series
por: Kang, Myoung Hee, et al.
Publicado: (2014)

Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
por: Liang, Lijun, et al.
Publicado: (2017)

Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma: Case Report
por: Yang, Biao, et al.
Publicado: (2017)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2021)

Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
por: Lagenfelt, Hanna, et al.
Publicado: (2021)

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

A Phase II Study of Gemcitabine, Vincristine, and Cisplatin (Gvp) As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma
por: Luo, Zhiguo, et al.
Publicado: (2015)

dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study
por: Xiong, Junjie, et al.
Publicado: (2016)

The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis
por: Fei, Qian, et al.
Publicado: (2021)

Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
por: Ouyang, Guoqing, et al.
Publicado: (2021)

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials
por: Zhong, Sheng, et al.
Publicado: (2017)

Hsa_circ_0007401 regulates gemcitabine resistance of pancreatic cancer through the hsa-miR-6509-3p/fli1 axis
por: Han, Chenchen, et al.
Publicado: (2023)

The systemic treatment of uterine leiomyosarcomas: A systematic review. No news is good news?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2021)

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)
por: Yang, Jiaying, et al.
Publicado: (2016)

Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer
por: An, Yuzhi, et al.
Publicado: (2015)

Multifocal extranodal lymphoma: A case report
por: Li, Chao, et al.
Publicado: (2016)

Oral plasmablastic lymphoma: A case report
por: Zizzo, Maurizio, et al.
Publicado: (2020)

Is Pathologic Near-Total Regression an Appropriate Indicator of a Good Response to Preoperative Chemoradiotherapy Based on Oncologic Outcome of Disease?
por: Kim, Jee Yeon, et al.
Publicado: (2015)

Identification of an immune-related 6-lncRNA panel with a good performance for prognostic prediction in hepatocellular carcinoma by integrated bioinformatics analysis
por: Lu, Shan, et al.
Publicado: (2023)

Argon plasma coagulation with atezolizumab and chemoradiation in lung pleomorphic cancer showed a remarkable response: Case report
por: Harada, Masanori, et al.
Publicado: (2021)

Plasmablastic lymphoma: Review of 60 Chinese cases and prognosis analysis
por: Han, Xiao, et al.
Publicado: (2017)

Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma
por: Liang, Xiao, et al.
Publicado: (2021)

Analysis of genomic alterations in primary central nervous system lymphoma
por: He, Xin, et al.
Publicado: (2023)

Primary cutaneous anaplastic large-cell lymphoma: A case report
por: Abed, Kamil, et al.
Publicado: (2018)

Primary testicular diffuse large B-cell lymphoma: Case series
por: Wang, Qi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ecip9kg1q4an085e2gl5c3np2v